ORIGINAL ARTICLE Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia Ivan O. Rosas, Norbert Bräu, Michael Waters, et al N Engl J Med February 25, 2021DOI: 10.1056/NEJMoa2028700 Abstract BACKGROUND Coronavirus disease 2019 (Covid-19) is associated with immune dysregulation and hyperinflammation, including elevated interleukin-6 levels. The use of tocilizumab, a monoclonal antibody against the interleukin-6 receptor, has resulted in better ...

2020年引用最多论文  Understanding the disease ~ Zang H. et al. - Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target Letter ~ Ruan Q. et al. ~Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China Guidelines ~ Alhazzani W. et al. - Surviving Sepsis Campaign: guidelines on the management of cr...

COVID-19 Consequences Six Months After Symptom Onset Findings from a follow-up study conducted with 1733 patients first diagnosed in Wuhan, China, show that nearly 76% of these patients had at least one symptom six months after symptom onset. Findings are published in The Lancet. The study included patients discharged from Jin Yin-tan Hospital in Wuhan, China, who were diagnosed with COVID-19 between January and May and who were followed to June and September. ...

Editorials Covid-19 controversies: the tocilizumab chapter Erin K McCreary, Nuala J Meyer BMJ 2021; 372: n244 doi: https://doi.org/10.1136/bmj.n244 The signals are broadly positive, but not definitive More than two million people have so far died from coronavirus disease 2019 (covid-19) globally. With hospitals and intensive care units at or exceeding capacity in much of the world, discovering life-saving treatments is second only to global vaccination effo...

表1. 怀疑或确诊产ESBL肠杆菌感染的推荐抗生素治疗选择（假设对表格中列举的抗生素体外敏感） 表2. 耐碳青霉烯肠杆菌(CRE)感染的推荐抗生素治疗选择（假设对表格中列举的抗生素体外敏感） 表3. 难治性耐药(DTR)铜绿假单胞菌感染的推荐抗生素治疗选择（假设对表格中列举的抗生素体外敏感）

ONLINE FIRST THIS WEEK(FREE ACCESS)  Original ~ Buetti N. et al. - COVID-19 increased the risk of ICU-acquired bloodstream infections: a case–cohort study from the multicentric OUTCOMEREA networkEditorial ~ Dale C.M. et al. - Leaving a mark: pressure injury research in the intensive care unitLetter ~ Proudfoot A.G. et al. - Rapid establishment of a COVID-19 critical care unit in a convention centre: the Nightingale Hospital London experienceCorrespondence ~ Meduri...

Research Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial Viviane C Veiga, João A G G Prats, Danielle L C Farias, et al BMJ 2021; 372: n84 doi: https://doi.org/10.1136/bmj.n84 Abstract Objective To determine whether tocilizumab improves clinical outcomes for patients with severe or critical coronavirus disease 2019 (covid-19). Design Randomised, open labe...

Original Investigation Caring for the Critically Ill PatientFebruary 23, 2021 Effect of Vitamin C, Thiamine, and Hydrocortisone on Ventilator- and Vasopressor-Free Days in Patients With Sepsis: The VICTAS Randomized Clinical Trial Jonathan E. Sevransky, Richard E. Rothman, David N. Hager, et al JAMA. 2021;325(8):742-750. doi:10.1001/jama.2020.24505 Abstract Importance Sepsis is a common syndrome with substantial morbidity and mortality. A ...

Original Investigation January 19, 2021 Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial Renato D. Lopes, Ariane V. S. Macedo, Pedro G. M. de Barros E Silva, et al JAMA. 2021;325(3):254-264. doi:10.1001/jama.2020.25864 Abstract Importance It is unknown whether angiotensin-c...

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial  RECOVERY Collaborative Group Lancet 2021; 397: 605–12  https://doi.org/10.1016/ S0140-6736(21)00149-5  Summary  Background Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatory actions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID...